[HTML][HTML] Importance of the immune microenvironment in the spontaneous regression of cervical squamous intraepithelial lesions (cSIL) and implications for …

CLP Muntinga, PJ de Vos van Steenwijk… - Journal of Clinical …, 2022 - mdpi.com
Cervical high-grade squamous intraepithelial lesions (cHSILs) develop as a result of a
persistent high-risk human papilloma virus (hrHPV) infection. The natural course of cHSIL is …

[HTML][HTML] A gene signature identifying CIN3 regression and cervical cancer survival

MK Halle, AC Munk, B Engesæter, S Akbari, A Frafjord… - Cancers, 2021 - mdpi.com
Simple Summary Through implementation of HPV testing as standard primary screening
method, the number of women diagnosed with high-grade cervical intraepithelial neoplasia …

[HTML][HTML] Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions

Z Abdulrahman, N Hendriks, AJ Kruse… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background The complete response rate of cervical high-grade squamous intraepithelial
lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently …

[HTML][HTML] Imiquimod for cervical and vaginal intraepithelial neoplasia: a systematic review and meta-analysis

Y Inayama, S Takamatsu, J Hamanishi… - Obstetrics & …, 2022 - journals.lww.com
OBJECTIVE: To evaluate the treatment efficacy and the risk of adverse events of imiquimod
for cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VAIN) …

[HTML][HTML] Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions

Y Hu, Y Li, Y Xu, Y Teng, J Chen, L Ma - Photodiagnosis and Photodynamic …, 2022 - Elsevier
Objective To evaluate the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
in the treatment of high-grade squamous intraepithelial lesions of the cervix (HSIL). Methods …

[HTML][HTML] 9-oxo-ODAs suppresses the proliferation of human cervical cancer cells through the inhibition of CDKs and HPV oncoproteins

K Mogi, Y Koya, M Yoshihara, M Sugiyama, R Miki… - Scientific reports, 2023 - nature.com
Mucosal human papillomavirus (HPV) subtypes 16 and 18 are causative agents of cervical
cancer, a leading cause of cancer-related deaths among women worldwide. In Japan …

Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions …

SS Sheth, JE Oh, S Bellone, ER Siegel… - Clinical Cancer …, 2024 - AACR
Purpose: We report the results of a randomized phase II trial of imiquimod, a topical immune-
response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine …

[HTML][HTML] Topical imiquimod cream for the treatment of cervical intraepithelial neoplasia

HY Oo, SMM Lwin, AL Thu, K San Myint… - The Cochrane …, 2024 - ncbi.nlm.nih.gov
Topical imiquimod cream for the treatment of cervical intraepithelial neoplasia - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

[HTML][HTML] Imiquimod Is Effective in Reducing Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis

B Hamar, B Teutsch, E Hoffmann, P Hegyi, A Harnos… - Cancers, 2024 - mdpi.com
Simple Summary There are publications on the use of Imiquimod in cervical intraepithelial
neoplasia (CIN) and HPV clearance; however, the literature is not consistent about its …

[HTML][HTML] YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of …

S Li, X Li, Y Yang, S Wu - Apoptosis, 2024 - Springer
A number of studies have confirmed that Yes-associated protein (YAP)/transcriptional co-
activator with PDZ-binding motif (TAZ)-transcriptional enhanced associate domain (TEAD) …